{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:12:38Z","timestamp":1790863958225,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"DOI":"10.1007\/s40520-026-03391-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T14:36:19Z","timestamp":1775918179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology"],"prefix":"10.1007","volume":"38","author":[{"given":"Angelo","family":"Semeraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Chial\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Fanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Di Tano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Dibenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"3391_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention D and T","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention D and T (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA: J Am Med Association 285:785\u2013795. https:\/\/doi.org\/10.1001\/jama.285.6.785","journal-title":"JAMA: J Am Med Association"},{"key":"3391_CR2","unstructured":"WHO (1994) Assessment of fracture risk and its application to screeniung for postmenopausal osteoporosis: Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1\u2013129"},{"key":"3391_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41574-020-00426-5","volume":"17","author":"EG Estell","year":"2021","unstructured":"Estell EG, Rosen CJ (2021) Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol 17:31\u201346. https:\/\/doi.org\/10.1038\/s41574-020-00426-5","journal-title":"Nat Rev Endocrinol"},{"key":"3391_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66:1139\u20131146. https:\/\/doi.org\/10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"},{"key":"3391_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","volume":"96","author":"GL Galea","year":"2017","unstructured":"Galea GL, Lanyon LE, Price JS (2017) Sclerostin\u2019s role in bone\u2019s adaptive response to mechanical loading. Bone 96:38\u201344. https:\/\/doi.org\/10.1016\/j.bone.2016.10.008","journal-title":"Bone"},{"key":"3391_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biocel.2016.05.015","volume":"77","author":"P Duan","year":"2016","unstructured":"Duan P, Bonewald LF (2016) The role of the wnt\/\u03b2-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol 77:23\u201329. https:\/\/doi.org\/10.1016\/j.biocel.2016.05.015","journal-title":"Int J Biochem Cell Biol"},{"key":"3391_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/8755122520967632","volume":"37","author":"SA Miller","year":"2021","unstructured":"Miller SA, St. Onge EL, Whalen KL (2021) Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis. J Pharm Technol 37:45\u201352. https:\/\/doi.org\/10.1177\/8755122520967632","journal-title":"J Pharm Technol"},{"key":"3391_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"3391_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","volume":"77","author":"C Prather","year":"2020","unstructured":"Prather C, Adams E, Zentgraf W (2020) Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis. Am J Health-System Pharm 77:1949\u20131956. https:\/\/doi.org\/10.1093\/ajhp\/zxaa285","journal-title":"Am J Health-System Pharm"},{"key":"3391_CR10","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S et al (2018) A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"key":"3391_CR11","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","journal-title":"Lancet"},{"key":"3391_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"3391_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S et al (2018) Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J Bone Miner Res 33:1407\u20131416. https:\/\/doi.org\/10.1002\/jbmr.3439","journal-title":"J Bone Miner Res"},{"key":"3391_CR14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"3391_CR15","doi-asserted-by":"publisher","unstructured":"Inose H, Ariga A, Motoyoshi T et al (2022) The Real-World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study. JBMR Plus 6. https:\/\/doi.org\/10.1002\/jbm4.10637","DOI":"10.1002\/jbm4.10637"},{"key":"3391_CR16","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","volume":"11","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M et al (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11:11801. https:\/\/doi.org\/10.1038\/s41598-021-91248-6","journal-title":"Sci Rep"},{"key":"3391_CR17","doi-asserted-by":"publisher","unstructured":"Damm T, Libanati C, Pe\u00f1a J et al (2025) Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density. JBMR Plus 9. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf119","DOI":"10.1093\/jbmrpl\/ziaf119"},{"key":"3391_CR18","unstructured":"National Osteoporosis Guideline Group (NOGG) (2022) NOGG\u2013ROS Advisory Statement on the prioritisation of romosozumab. for the treatment of severe osteoporosis"},{"key":"3391_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00774-024-01531-5","volume":"42","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Hara M, Shimanoe C et al (2024) Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. J Bone Min Metab 42:492\u2013502. https:\/\/doi.org\/10.1007\/s00774-024-01531-5","journal-title":"J Bone Min Metab"},{"key":"3391_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jot.2024.07.011","volume":"48","author":"RMY Wong","year":"2024","unstructured":"Wong RMY, Wong PY, Liu C et al (2024) Treatment effects, adverse outcomes and cardiovascular safety of romosozumab \u2013 Existing worldwide data: A systematic review and meta-analysis. J Orthop Translat 48:107\u2013122. https:\/\/doi.org\/10.1016\/j.jot.2024.07.011","journal-title":"J Orthop Translat"},{"key":"3391_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4103\/ijri.IJRI_495_19","volume":"30","author":"M Qutbi","year":"2020","unstructured":"Qutbi M, Soltanshahi M, Shiravand Y et al (2020) Technical and patient-related sources of error and artifacts in bone mineral densitometry using dual-energy X-ray absorptiometry: A pictorial review. Indian J Radiol Imaging 30:362\u2013371. https:\/\/doi.org\/10.4103\/ijri.IJRI_495_19","journal-title":"Indian J Radiol Imaging"},{"key":"3391_CR22","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ultrasmedbio.2016.01.024","volume":"42","author":"S Casciaro","year":"2016","unstructured":"Casciaro S, Peccarisi M, Pisani P et al (2016) An Advanced Quantitative Echosound Methodology for Femoral Neck Densitometry. Ultrasound Med Biol 42:1337\u20131356. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2016.01.024","journal-title":"Ultrasound Med Biol"},{"key":"3391_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ultrasmedbio.2014.08.017","volume":"41","author":"F Conversano","year":"2015","unstructured":"Conversano F, Franchini R, Greco A et al (2015) A Novel Ultrasound Methodology for Estimating Spine Mineral Density. Ultrasound Med Biol 41:281\u2013300. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2014.08.017","journal-title":"Ultrasound Med Biol"},{"key":"3391_CR24","doi-asserted-by":"publisher","first-page":"115786","DOI":"10.1016\/j.bone.2020.115786","volume":"143","author":"B Cortet","year":"2021","unstructured":"Cortet B, Dennison E, Diez-Perez A et al (2021) Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis in a European multicenter clinical context. Bone 143:115786. https:\/\/doi.org\/10.1016\/j.bone.2020.115786","journal-title":"Bone"},{"key":"3391_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-018-4686-3","volume":"30","author":"M Di Paola","year":"2019","unstructured":"Di Paola M, Gatti D, Viapiana O et al (2019) Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int 30:391\u2013402. https:\/\/doi.org\/10.1007\/s00198-018-4686-3","journal-title":"Osteoporos Int"},{"key":"3391_CR26","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/jum.15665","volume":"40","author":"MD Tomai Pitinca","year":"2021","unstructured":"Tomai Pitinca MD, Fortini P, Gonnelli S, Caffarelli C (2021) Could Radiofrequency Echographic Multi-Spectrometry (<\u2009scp>REMS) Overcome the Limitations of <\u2009scp>BMD\u2009by <scp\u2009>\u2009DXA Related to Artifacts? A Series of 3 Cases<\/scp\u2009>. J Ultrasound Med 40:2773\u20132777. https:\/\/doi.org\/10.1002\/jum.15665","journal-title":"J Ultrasound Med"},{"key":"3391_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12891-022-05430-6","volume":"23","author":"C Caffarelli","year":"2022","unstructured":"Caffarelli C, Tomai Pitinca MD, Al Refaie A et al (2022) Could radiofrequency echographic multispectrometry (REMS) overcome the overestimation in BMD by dual-energy X-ray absorptiometry (DXA) at the lumbar spine? BMC Musculoskelet Disord 23:469. https:\/\/doi.org\/10.1186\/s12891-022-05430-6","journal-title":"BMC Musculoskelet Disord"},{"key":"3391_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40520-019-01294-4","volume":"31","author":"A Diez-Perez","year":"2019","unstructured":"Diez-Perez A, Brandi ML, Al-Daghri N et al (2019) Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art\u2014outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 31:1375\u20131389. https:\/\/doi.org\/10.1007\/s40520-019-01294-4","journal-title":"Aging Clin Exp Res"},{"key":"3391_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40520-024-02784-w","volume":"36","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Reginster J-Y, Al-Daghri N et al (2024) Radiofrequency echographic multi spectrometry (REMS) in the diagnosis and management of osteoporosis: state of the art. Aging Clin Exp Res 36:135. https:\/\/doi.org\/10.1007\/s40520-024-02784-w","journal-title":"Aging Clin Exp Res"},{"key":"3391_CR30","unstructured":"R Core Team (2025) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing,Vienna, Austria. https:\/\/www.R-project.org\/"},{"key":"3391_CR31","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00198-025-07722-8","volume":"36","author":"G Adami","year":"2025","unstructured":"Adami G, Bartezaghi M, Montanari F et al (2025) ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. Osteoporos Int 36:2459\u20132469. https:\/\/doi.org\/10.1007\/s00198-025-07722-8","journal-title":"Osteoporos Int"},{"key":"3391_CR32","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K et al (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32:1999\u20132009. https:\/\/doi.org\/10.1007\/s00198-021-05925-3","journal-title":"Osteoporos Int"},{"key":"3391_CR33","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88:105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"key":"3391_CR34","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study. Bone Rep 14:101068. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"key":"3391_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00198-024-07019-2","volume":"35","author":"K Ebina","year":"2024","unstructured":"Ebina K, Nagayama Y, Kashii M et al (2024) An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case\u2013control study. Osteoporos Int 35:841\u2013849. https:\/\/doi.org\/10.1007\/s00198-024-07019-2","journal-title":"Osteoporos Int"},{"key":"3391_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1359\/jbmr.2000.15.1.24","volume":"15","author":"LJ Melton","year":"2000","unstructured":"Melton LJ, Atkinson EJ, O\u2019Connor MK et al (2000) Determinants of Bone Loss from the Femoral Neck in Women of Different Ages. J Bone Miner Res 15:24\u201331. https:\/\/doi.org\/10.1359\/jbmr.2000.15.1.24","journal-title":"J Bone Miner Res"},{"key":"3391_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00774-025-01590-2","volume":"43","author":"T Kobayakawa","year":"2025","unstructured":"Kobayakawa T (2025) Sequential and combination therapy with romosozumab. J Bone Min Metab 43:10\u201317. https:\/\/doi.org\/10.1007\/s00774-025-01590-2","journal-title":"J Bone Min Metab"},{"key":"3391_CR38","doi-asserted-by":"publisher","first-page":"117389","DOI":"10.1016\/j.bone.2025.117389","volume":"193","author":"K Ebina","year":"2025","unstructured":"Ebina K, Kobayakawa T, Etani Y et al (2025) Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study. Bone 193:117389. https:\/\/doi.org\/10.1016\/j.bone.2025.117389","journal-title":"Bone"},{"key":"3391_CR39","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H et al (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574. https:\/\/doi.org\/10.1016\/j.bone.2020.115574","journal-title":"Bone"},{"key":"3391_CR40","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00198-020-05815-0","volume":"32","author":"EV McCloskey","year":"2021","unstructured":"McCloskey EV, Johansson H, Harvey NC et al (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int 32:1601\u20131608. https:\/\/doi.org\/10.1007\/s00198-020-05815-0","journal-title":"Osteoporos Int"},{"key":"3391_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bone.2016.04.003","volume":"88","author":"J Wang","year":"2016","unstructured":"Wang J, Stein EM, Zhou B et al (2016) Deterioration of trabecular plate-rod and cortical microarchitecture and reduced bone stiffness at distal radius and tibia in postmenopausal women with vertebral fractures. Bone 88:39\u201346. https:\/\/doi.org\/10.1016\/j.bone.2016.04.003","journal-title":"Bone"},{"key":"3391_CR42","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s11999-009-0751-8","volume":"467","author":"JM Kreider","year":"2009","unstructured":"Kreider JM, Goldstein SA (2009) Trabecular Bone Mechanical Properties in Patients with Fragility Fractures. Clin Orthop Relat Res 467:1955\u20131963. https:\/\/doi.org\/10.1007\/s11999-009-0751-8","journal-title":"Clin Orthop Relat Res"},{"key":"3391_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","volume":"81","author":"C Graeff","year":"2015","unstructured":"Graeff C, Campbell GM, Pe\u00f1a J et al (2015) Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone 81:364\u2013369. https:\/\/doi.org\/10.1016\/j.bone.2015.07.036","journal-title":"Bone"},{"key":"3391_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.11005\/jbm.2021.28.4.317","volume":"28","author":"C Jeong","year":"2021","unstructured":"Jeong C, Kim J, Lim Y et al (2021) Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis. J Bone Metab 28:317\u2013323. https:\/\/doi.org\/10.11005\/jbm.2021.28.4.317","journal-title":"J Bone Metab"},{"key":"3391_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jbmr\/zjae194","volume":"40","author":"MR McClung","year":"2025","unstructured":"McClung MR, Betah D, Leder BZ et al (2025) Romosozumab improves microarchitecture as assessed by tissue thickness\u2013adjusted trabecular bone score in postmenopausal women with osteoporosis. J Bone Miner Res 40:193\u2013200. https:\/\/doi.org\/10.1093\/jbmr\/zjae194","journal-title":"J Bone Miner Res"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-026-03391-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03391-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:53:16Z","timestamp":1779414796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-026-03391-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1007\/s40520-026-03391-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9116907\/v1","asserted-by":"object"}]},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Review Board of the participating hospital, and it was conducted in accordance with the ethical standards of the Declaration of Helsinki (1964).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Informed consent for participation and publication has been obtained from all the participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"137"}}